Regeneron Stock Hits New 52-Week High (REGN) - TheStreet

NEW YORK (

TheStreet

) --

Regeneron Pharmaceuticals

(Nasdaq:

REGN

) hit a new 52-week high Monday as it is currently trading at $119.58, above its previous 52-week high of $119.41 with 50,811 shares traded as of 9:35 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Regeneron has a market cap of $7.18 billion and is part of the

health care

sector and

drugs

industry. Shares are up 115% year to date as of the close of trading on Friday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Regeneron as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full

Regeneron Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null